Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

29.59
+0.87003.03%
Post-market: 29.590.00000.00%19:13 EDT
Volume:333.18K
Turnover:9.81M
Market Cap:1.09B
PE:-48.74
High:29.67
Open:29.01
Low:28.96
Close:28.72
Loading ...

Opaleye Management Inc. Reports Disposal of Common Shares of Harrow Inc

Reuters
·
Yesterday

Opaleye Management Inc. Reports Disposal of Common Shares of Harrow Inc

Reuters
·
15 May

Harrow Inc. to Participate in B. Riley Securities Annual Investor Conference

Reuters
·
14 May

Harrow price target lowered to $54 from $58 at Craig-Hallum

TIPRANKS
·
12 May

Harrow Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

Harrow Q1 Adj. EPS $(0.38) Misses $(0.05) Estimate, Sales $47.83M Miss $57.00M Estimate

Benzinga
·
09 May

Harrow Inc. Reports 38% Revenue Increase to $47.8M and $(17.8)M GAAP Net Loss in Q1 2025

Reuters
·
09 May

Harrow Health Q1 EPS USD -0.5

THOMSON REUTERS
·
09 May

Harrow Health Q1 Core Gross Margin 75%

THOMSON REUTERS
·
09 May

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

TIPRANKS
·
08 May

Press Release: Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Dow Jones
·
05 May

3 Growth Stocks Insiders Are Betting On

Simply Wall St.
·
29 Apr

Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment

MT Newswires Live
·
25 Apr

Nordic Group B.v. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Launch of Authorized Generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

THOMSON REUTERS
·
24 Apr

Nordic Pharma - Partners With Harrow to Launch Generic Maxitrol

THOMSON REUTERS
·
24 Apr

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

GuruFocus.com
·
22 Apr

BRIEF-Harrow - Klarity-C Patients To Access Vevye For $59 Per Bottle

Reuters
·
10 Apr

Harrow Inc - Klarity-C Patients to Access Vevye for $59 per Bottle

THOMSON REUTERS
·
10 Apr

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Business Wire
·
10 Apr

Harrow Is Maintained at Buy by B. Riley Securities

Dow Jones
·
02 Apr